Jon Cuthbert

NRx Pharmaceuticals (NASDAQ:NRXP) secured FDA authorization for a depression treatment protocol with an initial drug cost of $0.

Biotechnology firm bioAffinity Technologies (NASDAQ:BIAF) announced preclinical findings showing its novel small interfering RNA therapeutic approach selectively destroys cells from two common skin cancers that affect an estimated 5.4 million annual United States cases.

REGENXBIO (NASDAQ:RGNX) aligned with the FDA to resubmit its rare disease drug application in Q3 2026.

AbbVie (NYSE:ABBV) executed an agreement to acquire Apogee Therapeutics (NASDAQ:APGE) for $135.11 per share in cash, totaling approximately $10.9 billion.

MOGU (NYSE:MOGU) posted an 11.2% decline in fiscal year 2026 total revenues to RMB125.4 million due to heightened competition.

BioArctic partnered with Eli Lilly (NYSE:LLY) on a neurodegeneration drug deal potentially worth $770 million.

LAB (CRYPTO:LAB) climbed 27.96% to US$15.48 over the past 24 hours, outperforming Bitcoin (CRYPTO:BTC), which gained 0.97%, as buyers defended a key support zone near US$12.

Franklin Templeton has filed plans with the US Securities and Exchange Commission for two exchange-traded funds that combine US equities with Bitcoin (CRYPTO:BTC) exposure through dividend reinvestment.

The Independent Community Bankers of America has asked the Federal Reserve Bank of Kansas City to reassess Kraken Financial's limited-purpose Federal Reserve account.

The price of Brent crude rose by more than US$1 to US$81.66 a barrel following the conclusion of diplomatic talks between the United States and Iran in Switzerland.